News

FDA Approves Cancer Drugs Faster Than European Agency


 

Dr. Marshall said that the market for cancer drugs is changing rapidly. "We have a shifting model from where everybody with breast cancer is going to get Taxol, to certain patients are going to get certain medicines," he said, adding that this shrinks the overall market for a product and thus, probably the interest in investing in that therapy.

Pages

Recommended Reading

Screen Breast Cancer Patients for Depression
MDedge Hematology and Oncology
New Cancer Patients Struggle to Get Appointments
MDedge Hematology and Oncology
FDA Adds Warnings About High-Grade Prostate Cancer to BPH Drug Labels
MDedge Hematology and Oncology
Axitinib Extends Progression-Free Survival in Kidney Cancer Trial
MDedge Hematology and Oncology
Protein Expression Marker May Predict Response to Anthracyclines
MDedge Hematology and Oncology
FDA Approves Test for HER2 Gene in Breast Cancer Tissue
MDedge Hematology and Oncology
European Trial Upholds Use of Erlotinib in EGFR-Mutant Lung Cancer
MDedge Hematology and Oncology
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
MDedge Hematology and Oncology
Iniparib Loses Blockbuster Image in Triple-Negative Breast Cancer
MDedge Hematology and Oncology
Chemo Length May Not Affect Survival in Some B-cell Lymphomas
MDedge Hematology and Oncology